• Antibody-Drug Conjugates and Endometrial Cancer: Combinations, Response Rates, and Clinical Trials

  • Jun 25 2024
  • Length: 28 mins
  • Podcast

Antibody-Drug Conjugates and Endometrial Cancer: Combinations, Response Rates, and Clinical Trials

  • Summary

  • Drs Ursula A. Matulonis and Kathleen N. Moore discuss the different aspects of antibody-drug conjugates (ADCs) in endometrial cancer, medications that are currently available, and promising HER2 ADCs.

    Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999848. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Uterine Neoplasms Version 2.2024 — March 6, 2024 https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

    DESTINY-PanTumor-02: Trastuzumab Deruxtecan Has Activity Against a Range of HER2-Expressing Solid Tumors https://dailynews.ascopubs.org/do/destiny-pantumor-02-trastuzumab-deruxtecan-has-activity-against-range-her2-expressing

    LBA34 - Trastuzumab Deruxtecan (T-DXd) for Pretreated Patients (pts) With HER2-Expressing Solid Tumors: Primary Analysis From the DESTINY-PanTumor02 (DP-02) Study https://oncologypro.esmo.org/meeting-resources/esmo-congress/trastuzumab-deruxtecan-t-dxd-for-pretreated-patients-pts-with-her2-expressing-solid-tumors-primary-analysis-from-the-destiny-pantumor02-dp-02

    Uterine Serous Carcinoma https://pubmed.ncbi.nlm.nih.gov/33934848/

    A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma https://www.nrgoncology.org/Clinical-Trials/Protocol/nrg-gy026?filter=nrg-gy026

    Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10730032/

    HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology https://pubmed.ncbi.nlm.nih.gov/27841667/

    Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial https://pubmed.ncbi.nlm.nih.gov/36977309/

    A Study of DB-1303 in Advanced/Metastatic Solid Tumors https://clinicaltrials.gov/study/NCT05150691

    DNA Mismatch Repair Proteins: Scientific Update and Practical Guide https://pubmed.ncbi.nlm.nih.gov/33597222/

    A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) https://clinicaltrials.gov/study/NCT04209855

    PRO1184 for Advanced Solid Tumors (PRO1184-001) https://www.clinicaltrials.gov/study/NCT05579366

    A New Wave of Innovations Within the DNA Damage Response https://pubmed.ncbi.nlm.nih.gov/37679326/

    Center for DNA Damage and Repair https://www.dana-farber.org/research/integrative-research/dna-damage-and-repair

    The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions https://pubmed.ncbi.nlm.nih.gov/33806979/

    Genomic Landscape of Endometrial Carcinomas of No Specific Molecular Profile https://pubmed.ncbi.nlm.nih.gov/35365770/

    The Emerging Genomic Landscape of Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/24170611/

    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Antibody-Drug Conjugates and Endometrial Cancer: Combinations, Response Rates, and Clinical Trials

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.